8-KOther EventsExhibits & Filings

Cencora, Inc. 8-K Report, Corporate Update (Nov 2, 2006)

Filed November 2, 2006For Securities:COR

Summary

AmerisourceBergen Corporation (now Cencora, Inc.) filed an 8-K report on November 1, 2006, detailing two significant events. First, the company announced the acquisition of IgG of America, Inc., a specialty pharmacy focusing on IVIG blood derivative treatments, for approximately $35 million in cash. This strategic move appears to bolster AmerisourceBergen's presence in the high-growth specialty pharmacy sector, particularly in infusion services. Second, the report includes a press release regarding the company's financial results for the fiscal quarter and full year ended September 30, 2006, along with the announcement of its earnings conference call. While the specific financial details are not detailed within the 8-K itself but referenced via an exhibit, this dual announcement highlights both inorganic growth through acquisition and the company's ongoing operational performance reporting to investors.

Key Highlights

  • 1Acquisition of IgG of America, Inc. for approximately $35 million in cash.
  • 2IgG of America, Inc. is a specialty pharmacy and infusion services business focused on IVIG blood derivatives.
  • 3The acquisition signifies an expansion into the specialty pharmacy market.
  • 4The report also announces earnings for the fiscal quarter and year ended September 30, 2006.
  • 5An earnings conference call was scheduled to discuss the financial results.
  • 6The company's name at the time of the filing was AmerisourceBergen Corporation.

Frequently Asked Questions

While not explicitly detailed in the 8-K, the acquisition of IgG of America, Inc., a specialty pharmacy focusing on IVIG blood derivatives and infusion services, suggests AmerisourceBergen aimed to strengthen its position in the growing specialty pharmaceutical market and expand its service offerings in this niche area.

The 8-K filing announces that AmerisourceBergen released its earnings for the fiscal quarter and year ended September 30, 2006, via a press release (Exhibit 99.2). The specific financial figures are not included in the 8-K document itself but were made available through that press release and a subsequent conference call.

AmerisourceBergen acquired all of the outstanding stock of IgG of America, Inc. for approximately $35 million in cash.

IVIG stands for Intravenous Immunoglobulin. It is a treatment derived from human blood plasma, used to treat a variety of immune system deficiencies and autoimmune diseases.